True. But our advantage is that, even if prices are kept "affordable", GNBT/NGIO can still benefit in an exponential fashion, due to their size and relatively low overhead (as compared to BP).
I own a bunch of PFE and MRK. Numerous times, an approval worth a billion dollars doesn't even move the SP. Not the case with us. Even at a couple of bucks a dose, this is big-time money for us!
(2)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links